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Using in vitro models for assessing drug-bug crosstalk
Screening for responsive/not responsive
Batch system 
• 8 donors 
• 16 h (proximal colon conditions)
• Clinical CX dose + carrier (PEG)
Long term supplementation
M-SHIME system 
• 2 donors  
• 2wk stabilization +2wk 
treatment + 1wk washout
• Clinical CX dose + carrier 
(PEG)
Donor 6 Donor 8
Interactions between microbial- and host-derived metabolism











































































• Butyrate follows same trend 
observed in the batch
• CX impacts bacterial protein 
synthesis activity in mucus
• CX triggers translocation of Megamonas from 













Megamonas decreases in lumen 









• Microbiome functionality (GC)
• Community composition (NGS)
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